AbbVie Inc (ABBV)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
ABBV
AbbVie Inc
$262.82
+1.11%
HEALTHCARE · Cap: $454.36B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$1.94
-3.00%
HEALTHCARE · Cap: $144.85M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 326315% more annual revenue ($64.39B vs $19.73M). ABBV leads profitability with a 9.8% profit margin vs 6.0%. ZJYL trades at a lower P/E of 9.7x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
ZJYL
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$152.16
Current Price
$262.82
$110.66 premium
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.7% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : ZJYL
The strongest argument for ZJYL centers on P/E Ratio, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ZJYL carries more volatility with a beta of 7.33 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 19/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?